| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.3 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.045 | 0.3 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.3 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.3 |